Last reviewed · How we verify

NCT05311904: VA-C-NEMUS

Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients

Completed Last updated 6 October 2023
What this trial tests

trial testing Survey in Neuromuscular Diseases in 1,388 participants. Completed in 3 February 2023.

Timeline
11 March 2021
Primary endpoint
3 February 2023
3 February 2023

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,388
Start date11 March 2021
Primary completion3 February 2023
Estimated completion3 February 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Adults 18 to 100, any sex, with Neuromuscular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The frequency of severe forms of COVID-19 is higher in people with neuromuscular disease and in severe cases and long hospital stays, the disability of some neuromuscular patients may worsen due to prolonged bed rest . Finally, the symptoms of certain diseases such as myasthenia gravis can worsen after an infection such as COVID-19. Thanks to an unprecedented research effort, vaccines are now available and others still in development. The first studies published in medical journals are reassuring about the efficacy and safety of these vaccines. However, they have been studied in the general population and we do not yet have specific information in neuromuscular patients. This is the reason why the Va-C-NEMUS observatory was launched.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Survey

Trials testing the same drug.

Other recruiting trials for Neuromuscular Diseases

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05311904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing